BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain
BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements in sleep apnea, otitis media, and BMI.
BridgeBio's medicine helped people with a growth condition feel better in many ways—not just getting taller, but sleeping better and staying healthier too. When a medicine does more good things than expected, it can make people more interested in the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.